Metabolic Dysfunction-associated Steatotic Liver Disease and Chronic Kidney Disease: From Epidemiology and Pathophysiology to Clinical Prediction and Treatment Options (IMAGE)
Caption
This figure shows the evolution of terminology and diagnostic criteria from NAFLD to MAFLD and MASLD, with a focus shifting from “excluding other diseases” to “proactively identifying metabolic risk”, emphasizing metabolic dysfunction as a core driver of disease. In current clinical practice, the terms MAFLD and MASLD are used interchangeably. NAFLD, non-alcoholic fatty liver disease; MAFLD, metabolic dysfunction-associated fatty liver disease; MASLD, metabolic dysfunction-associated steatotic liver disease; BMI, body mass index; T2DM, type 2 diabetes mellitus; HDL, high-density lipoprotein; HbA1c, glycosylated hemoglobin.
Credit
Huiying Rao
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted.
License
CC BY-NC